ArticleNutrition journal2026
The prognostic impact of tryptophan on non-small cell lung cancer survival: insights from plasma essential amino acids.
Article in Nutrition journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundEssential amino acids (EAAs) play a critical role in the metabolism of both tumor and immune cells, thereby potentially affecting tumor prognosis via multiple mechanisms. However, few studies have explored the impact of individual or total EAA levels on the survival outcomes of patients with non-small cell lung cancer (NSCLC).
methodsMetabolomics technology was employed to measure plasma levels of eight EAAs and kynurenine (Kyn) in NSCLC patients. Cox proportional hazards regression model was applied to assess the association between individual EAA levels and the risk of NSCLC related mortality. The combined effect of EAAs on mortality risk in NSCLC patients was further evaluated using multiple statistical models including weighted quantile sum (WQS) regression, quantile-based g computation (qgcomp), and Bayesian kernel machine regression (BKMR) models. Finally, a Random Forest (RF) model was developed to evaluate the prognostic value of the Trp/Kyn ratio in predicting the mortality risk in NSCLC patients.
resultsA total of 422 NSCLC patients were included in the analyses. During the median follow-up period of 40.71 months, 300 deaths were recorded. Multivariable Cox regression analyses revealed that six EAAs were significantly associated with a reduced mortality risk, among which Trp exhibited the strongest inverse association (HR: 0.44, 95%CI: 0.31–0.62). More importantly, a significant inverse association between EAA levels and mortality risk was consistently identified across all three models, particularly in patients with advanced-stage NSCLC. Trp was confirmed as the primary contributor to this combined effect, especially in the advanced NSCLC subgroup. Furthermore, a higher Trp/Kyn ratio was associated with a reduced mortality risk in NSCLC patients. Integrating the Trp/Kyn ratio with key clinical factors (smoking status, cancer stage, and surgery) into a Random Forest model significantly enhanced the prediction of 5-year mortality (test set AUC: 0.759).
conclusionsThe plasma EAAs were inversely associated with the risk of death in NSCLC patients, especially in those with advanced-stage disease. Among the eight EAAs, Trp emerged as the primary contributor. The Trp/Kyn ratio served as a valuable biomarker for risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.